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SUMMARY
Introduction/Objective The aim of this paper was to verify the biocompatibility of the newly synthe-
sized nanostructured material based on calcium aluminate after implantation into the subcutaneous 
tissue of rats.
Methods The study included 18 rats aged 10–11 weeks, divided into two experimental groups (n = 9). 
In all animals, incision took place on the back and two pockets of 15 mm in depth were made, in which 
sterile polyethylene tubes with test materials [calcium aluminate cement (ALBO-CA), calcium silicate 
cement with the addition of hydroxyapatite (ALBO-CSHA), and mineral trioxide aggregate (MTA) for the 
control group) were implanted. Six rats of each group were sacrificed in three observational periods 
(seven, 15, 30 days). Pathohistological analysis included inflammation, bleeding, fibrous capsule, and 
tissue integrity around the implanted material.
Results After seven days of treatment, ALBO-CA and ALBO-CSHA showed better tissue response compared 
to MTA, with a statistically significant difference in inflammation intensity (p = 0.2781). The difference in 
vascular congestion and thickness of the fibrous capsule after implantation of ALBO-CA material com-
pared to MTA was also statistically significant (p = 0.5567). At the end of the 30-day evaluation period, an 
identical inflammatory response of connective tissue at the site of implanting ALBO-CA, ALBO-CSHA, and 
MTA (score of 0.7) was recorded. The formation of thick or moderately thick fibrous capsule was found 
to be the thickest in ALBO-CA (grade 3.7). There were no statistically significant differences between the 
parameters analyzed after 30 days. 
Conclusion Newly synthesized ALBO-CA showed a satisfactory tissue response and confirmed biocom-
patibility after implantation in subcutaneous tissue of rats.
Keywords: nanomaterials; calcium aluminates; calcium silicates; tissue reaction
INTRODUCTION
In recent years, tendencies of scientific research 
focused on the discovery of new biomaterials that 
would overcome the shortcomings of the exist-
ing ones through changes in composition and 
improved characteristics. In contact with tissue, 
biomaterials must not exhibit potential cytotoxic, 
genotoxic, mutagenic, or allergic reactions [1].
Biocompatibility tests are carried out in vitro 
and in vivo conditions and include testing of ma-
terials in laboratory conditions on cell tissues or 
organ cultures, animal experiments, and clinical 
tests on humans. The efficiency of animal tests 
is more important than in vitro research. These 
tests are carried out by using subcutaneous im-
plantation, allergy tests, and tests of acute and 
chronic systemic toxicity of dental materials [2].
Calcium aluminate cements (CAC) were de-
veloped at the beginning of the 20th century 
as chemically durable materials from Portland 
cement. Their hydraulic calcium phase con-
tains 30–50% of aluminum, while in Portland 
cement, aluminum is less than 5% [3, 4, 5].
More thorough studies of the potential bio-
medical application of calcium aluminate ce-
ments have been carried out a decade ago.
Attempts of calcium aluminates use in den-
tistry for direct restorative fillings on lateral 
teeth (DoxaDent; Doxa AB, Uppsala, Sweden) 
(Ceramir C&B, Doxa AB), during a three-year 
clinical monitoring did not indicate clinical 
success, due to inferior mechanical properties 
and handling difficulties [6, 7].
Calcium aluminate in addition to X-ray con-
trast agent, mixed with water or 0.9% saline 
solution, resulted in an endodontic cement of 
similar indications as commercially available 
tricalcium silicate cements (EndoBinder, Bind-
erweare, Sao Carlos, SP, Brazil). EndoBinder 
was developed with the intention of preserving 
the positive properties and clinical application 
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of mineral trioxide aggregate (MTA), but without its nega-
tive properties. According to the results of several recent 
studies, EndoBinder showed appropriate biological and 
physico-chemical characteristics, good antimicrobial activ-
ity against Enterococus fecalis, Staphylococcus aureus, and 
Candide albicans, and after the implantation into subcuta-
neous tissue of rats caused a minor inflammatory reaction 
compared to MTA or an inflammatory reaction similar 
to MTA [8–11]. During the repair of bone defects, Endo-
Binder showed similar behavior as MTA, and stimulated 
complete bone recovery after three months [12]. 
Quick-set (Primus Consulting, Bradenton, FL, USA), 
calcium aluminate cement, confirmed the dentinogenic 
potential as White Mineral Trioxide Aggregate (Dentsply 
Tulsa Dental Specialties, Tulsa, OK, USA) in in vitro con-
ditions on the MDPC-23 odontoblast cell line and in vivo 
conditions in pulpotomy [13, 14].
Attempts of combining calcium aluminate cements 
(CAC) with collagen, zirconium, zinc oxide, tricalcium 
phosphate, and hydroxyapatite have shown great potential 
for application in odontology and orthopedics. Compared 
with commercial products for implementation in dentistry 
(MTA, glass ionomer cement Vidrion; SSWhite Duflex, 
São Cristovão, RJ, Brasil) and orthopedics (polymethyl 
methacrylate), CAC mixtures showed greater alkaline 
phosphatase activity, higher cellular viability of osteoblast 
cells, and formation apatite on the surfaces of all CAC 
samples of homogeneous layer [15].
The combination of tricalcium aluminates (Ca3Al2O6) 
with tricalcium silicates (Ca3SiO5) resulted in better physi-
co-chemical properties (accelerated the hydration process, 
reduced the setting time and improved the compressive 
strength), higher bioactivity and biocompatibility (stimu-
lating effect on L929 cell growth) compared to pure trical-
cium silicates (Ca3SiO5) [16].
Despite the fact that in the last decade the emphasis has 
been placed on research of calcium aluminate cements, 
wider use of these materials in dental practice requires 
additional testing of a recent date.
Research on new calcium aluminates with similar physi-
cal and biological properties as well as MTA, but without 
its negative characteristics are still current.
Simultaneously, there is a growing influence of nano-
technology and nanomaterials in medicine.
The objective of this study was to investigate the bio-
compatibility of the newly synthesized nanostructured 
material based on calcium aluminate after implantation 
into the subcutaneous tissue of rats. 
METHODS
The research was conducted after the approval of the 
Ethics Committee of the University Clinical Center in Ban-
ja Luka, No. 01-9-192.2/15, Bosnia and Herzegovina, and 
an experiment was realized at the Vivarium of the Faculty 
of Natural Sciences and Mathematics, University of Banja 
Luka, and in the Laboratory of the Institute of Pathology, 
Banja Luka Clinical Center.
Tested materials
The calcium aluminate-based nanomaterial system (AL-
BO-CA) was compared to the hydroxyapatite and calcium 
silicate-based material (ALBO-CSHA). White Mineral Tri-
oxide Aggregate (MTA Angelus® Tulsa OK, USA) was used 
as a positive control.
The calcium aluminate system (CaO • Al2O3 + CaCO3 
+ Bi2O3) is a mixture called ALBO-MCCA, obtained by 
mixing CaCO3 and Bi2O3, and BaSO4 with a calcium alumi-
nate phase in the ratio of 2:2:1. In order to obtain calcium 
aluminate endodontic mixtures, it was first necessary to 
synthesize particular components of the mixture: calcium 
aluminate (CaO • Al2O3, CA) and calcite (CaCO3). The 
mixture was finally mixed with distilled water in the 2:1 
ratio of powder to water, according to the recommended 
protocol.
Another test material was calcium silicate with the ad-
dition of hydroxyapatite. Both of the materials were syn-
thesized according to the method of Professor Jokanović 
and his associate using new technology, a combination 
of hydrothermal sol-gel method and the method of self-
combusting waves [17]. 
Design of the study
The animal model comprised rats of the Wistar strain (18 
rats, aged 10–11 weeks, with the average weight of 190–280 
g). During the experiment, the rats had free access to food 
and water, 12-hour shifts of light and dark, air temperature 
ranged 20–23°C, and humidity was 60% ± 10%. The rats 
were divided into two experimental groups (n = 9). Six 
rats (three from each group) were sacrificed after seven, 
15 and 30 days. Subcutaneous implantation of polyeth-
ylene tubes (length 10 mm, inner diameter 1 mm) was 
conducted, up to half filled with tested materials (ALBO-
CA in group I, ALBO-CSHA in group II) and half empty. 
The empty half of the tube was the negative control. Two 
tubes were placed on the back of each rat, on the right side 
of the tube with the tested material, and on the left side 
of the spinal column of the tube with the MTA (positive 
control). The tubes were oriented so that the material was 
always turned toward the head, and the empty part of the 
tube to the tail.
Before the surgical procedure, the rats were put under 
general anesthesia (ketamine, 90 mg / kg of body weight, 
Ketamine Hydrochloride Injection USP, Rotexmedica 
GmbH Arzneimittelwerk, Trittau, Germany, in combina-
tion with xylazine, 5 mg / kg of body weight, 2% Xylazine, 
Cp Pharma, Bergdorf, Germany).
Preparation of the operational field was carried out, and 
then a blunt dissection, right and left of the spinal column, 
two pockets about 15 mm deep were formed. Sterile poly-
ethylene tubes, previously filled with freshly mixed test ma-
terials, were placed in the pockets in this way. After that, the 
wound was sewed. The individual knotted seam was applied.
After the operation, the animals were placed in one cage 
in the controlled environment, with controlled diet and 
daily professional care.
Biocompatibility of nanostructured biomaterials based on calcium aluminate
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Animal health control was carried out three times a 
day. Six animals were sacrificed in each observation period 
(seven, 15, 30 days). For this purpose, intravenous injec-
tion of pentobarbital (pentobarbital sodium salt, 100 mg/
ml, Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
was used.
Prepared subcutaneous tissue, together with tubes, was 
immersed in 10% formalin and delivered to laboratories 
for histological analysis.
For histological analysis, four samples were taken from 
each animal. After that, tissue clip fixation together with 
polyethylene tubes was performed in 10% buffered for-
malin, followed by paraffin molding and paraffinic dye-
ing by hematoxylin and eosin (4 μm thickness slices). The 
analysis of the preparation was done on a light microscope 
(Olympus BX-51, Olympus Corporation, Tokio, Japan) by 
an experienced pathologist, who did not participate in the 
sampling of the material.
Histological analysis of the prepared samples was per-
formed qualitatively and semi-quantitatively, and the in-
flammatory reaction, vascular congestion, fibrous capsule, 
and the preservation of the integrity of the connective tis-
sue were considered.
Statistical analysis
Dunn’s post-hoc test was applied for the significance of 
differences between pairs with a significance level of = 
0.05 for statistical analysis of the obtained subcutaneous 
implantation results. Statistical analysis was done in the 
Minitab 16 software package (Minitab INC, State College, 
PA, USA).
RESULTS
Results of the histological analysis are shown in Table 1 
and Figures 1–7.
After a seven-day histopathological analysis, a moder-
ate inflammatory reaction was recorded (grade 3) with 
calcium aluminate ALBO-CA and calcium silicate hy-
droxyapatite ALBO-CSHA, while inflammatory reaction 
with MTA was moderate (grade 3) in three cases, and 
an intensive inflammatory reaction (grade 4) was noted 
in three cases, with a statistically significant difference 
(p = 0.2781). Moderate inflammation was traced by mod-
erate vascular congestion with ALBO-CA (grade 3) and 
ALBO-CSHA material. After MTA implantation, equally 
moderate distribution (grade 3) and pronounced vas-
cular congestion were observed (grade 4). In all tested 
Table 1. Analyzes of inflammation, bleeding, fibrous capsules and integrity of binders of tested materials by observation periodicity 
Parameters 7 days 15 days 30 days
Inflammatory reaction ALBO-CA 3 ± 1.5 2 ± 1 0.666 ± 0.5
ALBO-CSHA 3 ± 1.5 2 ± 1 0.666 ± 0.5
MTA 3 ± 1.414 2 ± 1 1 ± 0.5
Vascular congestion ALBO-CA 3 ± 1.2777 2 ± 0.8888 0.6666 ± 0.5211
ALBO-CSHA 3.333 ± 0.5773 2.6666 ± 0.5773 0.6666 ± 0.57735
MTA 3.6667 ± 0.5773 2.6666 ± 0.5773 1 ± 0.0
Fibrous capsule ALBO-CA 1 ± 0.2778 2.3333 ± 1.156 4 ± 1.8888
ALBO-CSHA 0.6666 ± 0.5774 2.3333 ± 0.5775 3.3333 ± 0.57735
MTA 0.3333 ± 0.57735 2 ± 0.0 3.3333 ± 0.57735
Preserving the integrity of 
the connective tissue
ALBO-CA 3 ± 0.0 2 ± 0.0 1 ± 0.4444
ALBO-CSHA 3 ± 0.0 2 ± 0.0 0.6666 ± 0.57735
MTA 3 ± 0.0 2 ± 0.0 1 ± 0.0
ALBO-CA – calcium aluminate cement; ALBO-CSHA – calcium silicate cement with the addition of hydroxyapatite; MTA – mineral trioxide aggregate
Figure 1. Calcium aluminate cement (ALBO-CA) after the experimental 
period of seven days; there is a defect (from the tube) with a very thin 
capsule and moderate vascular congestion (H&E, × 100)
Figure 2. Calcium silicate cement with the addition of hydroxyapatite 
(ALBO-CSHA) after the experimental period of seven days; the fibrous 
capsule is not present (H&E, × 200)
DOI: https://doi.org/10.2298/SARH171211030J
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materials, a moderate distortion of the connective tissue 
structure was registered, while the fibrous capsule after the 
implantation of ALBO-CA material was minimal (grade 
1), i.e. minimal (grade 1) or absent (grade 0) after the 
implantation of ALBO-CSHA and MTA (Figures 1 and 
2). The difference in vascular congestion and the thick-
ness of the fibrous capsule after implantation of ALBO-
CA material relative to MTA was statistically significant 
(p = 0.5567).
In the control preparations, seven days after subcu-
taneous implantation, the presence of moderate inten-
sity inflammatory reaction and one case of pronounced 
inflammatory reaction was noted in the control of the 
ALBO-CA material and the MTA control. Blood vessels 
showed signs of moderate vascular congestion, which 
was more expressed in the control group of MTA. In all 
control preparations, there was a moderate disturbance 
of connective tissue structure, except in one case of the 
MTA control group with a slightly disrupted connective 
tissue structure (grade 2). The fibrous capsule was absent 
Figure 3. Calcium aluminate cement (ALBO-CA) after the experimental 
period of 15 days; there is a moderately thick capsule and mild vascular 
congestion and mild inflammation (H&E, × 400)
Figure 4. Calcium silicate cement with the addition of hydroxyapatite 
(ALBO-CSHA) after the experimental period of 15 days; there is a thin 
capsule and a mild inflammation reaction; lymphocytes and rare plas-
mocytes are present, which speaks in favor of a chronic inflammatory 
reaction (H&E, × 200)
Figure 5. Calcium aluminate cement (ALBO-CA) after the experimental 
period of 30 days; the microphotography reveals a thick capsule and 
mild vascular congestion and mild inflammation (H&E, × 400)
Figure 6. Calcium silicate cement with the addition of hydroxyapatite 
(ALBO-CSHA) after the experimental period of 30 days; implantation 
in the subcutaneous fat tissue is encircled by a thick capsule without 
inflammatory response and congestion (H&E, × 200)
Figure 7. Negative control (empty tube) after the experimental period 
of 30 days; the microphotography reveals a thick capsule and a mild 
vascular congestion and mild inflammation (H&E, × 400)
Biocompatibility of nanostructured biomaterials based on calcium aluminate
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in all control preparations of ALBO-CA, and in most of 
the preparations of the MTA control group, except in one 
case. Material control of ALBO-CSHA recorded a gentle 
thin capsule in two cases (grade 1), and complete absence 
of the capsule in one sample (grade 0).
A pathohistological analysis after 15 days at the site of 
implantation of all examined materials showed a slight 
inflammatory reaction thin or moderately thick fibrous 
capsule (Figures 3 and 4), and a mild disturbance of the 
connective tissue structure (grade 2). Vascular congestion 
is characterized as mild (grade 2) with the ALBO-CA ma-
terial, or as moderate or mild to ALBO-CSHA and MTA, 
with a statistically significant difference (p = 0.2974).
In control preparations after 15 days, the weakest in-
flammatory response was recorded in the ALBO-CSHA 
control (grade 2), while control preparations for ALBO-
CA were rated with mark 3 (moderate inflammatory re-
sponse), and for MTA the score was 2.3 (mild to moder-
ate inflammatory reaction). In all control preparations, a 
slight disturbance of the structure of the loose connective 
tissue (grade 2) was observed, followed by the formation 
of a thin fibrous capsule (grade 2). Vascular congestion 
was equally expressed in control group of ALBO-CSHA 
and MTA (grade 2.3), while in the ALBO-CA control, the 
score was rated 2.6.
At the end of the evaluation period of 30 days, an iden-
tical inflammatory response of loose connective tissue at 
the site of implantation ALBO-CA, ALBO-CSHA, and 
MTA (score of 0.7) was recorded. The formation of thick 
or moderately thick fibrous capsules (Figures 5 and 6) was 
established, which was the thickest with ALBO-CA (grade 
3.7). There were no statistically significant differences be-
tween the analyzed parameters.
In control preparations after 30 days, a weaker inflam-
matory response, lower vascular congestion, and better 
integrity of the binders were observed in control samples of 
ALBO-CSHA and MTA (grade 0.7), compared with ALBO-
CA control (grade 1). A moderately thick or thick fibrous 
capsule was formed (Figure 7), thicker in the control of 
the MTA material (grade 3.2), while the ALBO-CA and 
ALBO-CSHA controls were rated 3.
DISCUSSION
Animal testing is a common method of checking new ma-
terials before their clinical examination.
There are almost no species and subspecies in the 
animal world that have not been used for the purposes 
of scientific research. However, when it comes to dental 
research, preference is given to rats. Although there are 
now hundreds of pureblooded and about fifty crossed rat 
strains, the strains most commonly used in dental experi-
ments are from Wistar and Sprague–Dawley strains. The 
advantage in dental research for these experimental ani-
mals is primarily the similarity between their and human 
molars. In addition, rats cannot vomit and are therefore 
frequently used as a starting model for numerous toxicity 
and carcinogenicity tests of dental materials. Of course, 
the advantage is their reasonable price and the possibility 
of simple securing. Like mice, rats have good reproductive 
skills and are well-grown in laboratory conditions [18].
Subcutaneous implants in rats are often used to evaluate 
the biological compatibility of various dental materials. 
The widespread use of this method comes from the fact 
that the implantation of the material into the subcutaneous 
tissue of the animal is accessible and simple, but also reli-
able in order to determine tissue irritation and the interac-
tion between the tissue and the material itself [4, 11, 17]. 
Local reactions to the implant can be quantitatively and 
qualitatively evaluated using various methods: histologi-
cal analysis, scanning electron microscopy, transmission 
electro-microscopy, histochemical analysis. However, the 
most common method for studying tissue compatibility of 
implanted material is histological analysis, and thickness 
of the fibrous capsule around the implant that is under the 
skin, which has been used as an indicator of the biocom-
patibility of the material for decades [19].
Although a wide range of different types of tubes are in 
use today – dentine [20], silicone [21], Teflon [3], polyeth-
ylene [22], polypropylene [23] – our choice were polyethyl-
ene tubes, considering their inert nature and wide applica-
tion. They do not cause a tissue reaction and in controlled 
and effective way expose tested material to the living tissue. 
They are easy to apply and sterilize [11, 17, 22].
Tissue around the tested materials showed the highest 
level of inflammation in the first seven days, with moderate 
damage to the structure of the connective tissue. The con-
nective tissue around the MTA showed signs of the most 
severe inflammatory reaction evaluated as moderate and 
pronounced inflammation. This is in line with the find-
ings of some other researchers (Lotfi et al. [24], Camilleri 
and Pitt Ford [25]) according to which a slightly more 
expressed initial inflammatory response to tissue implanta-
tion by MTA is explained by high pH of this material, long-
term follow-up of heat-trapping, as well as the stimulation 
of inflammatory cytokines.
In accordance with our results are also the results of the 
study by Opačić-Galić et al. [22], where seven days after 
the subcutaneous implantation of the nanostructured CS-
HA, CS and the control MTA, in rats of the Wistar strain, 
the strongest inflammatory response was given by MTA 
(3.30 ± 0.48), while for CS and CS-HA it was graded with 
3.00 ± 0.71.
The results of this research showed the correlation 
between the strength of the inflammatory response and 
the thickness of the fibrous capsule. With time lag, a 
decrease in intensity of inflammation was noticed, with 
an increase in the thickness of the fibrous capsule in all 
tested materials. Experimental calcium aluminate cement 
(ALBO-CA) at the end of the observation period, after 30 
days, caused an identical tissue reaction such as calcium 
silicate hydroxyapatite (ALBO-CSHA) and commercial 
mineral trioxide aggregate (MTA), with the best organized 
fibrous capsule around the material, which is probably 
due to the chemical nature and method of synthesis of 
this cement. The bioactivity of one material is also related 
to the method of its synthesis. The calcium aluminate 
DOI: https://doi.org/10.2298/SARH171211030J
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nanostructured biomaterial, which was tested in this study, 
was produced by nanotechnology, by combining two meth-
ods: hydrothermal sol-gel method and the self-combusting 
wave methods. According to Chen et al. [26], the materials 
obtained by sol-gel processes are more bioactive than those 
obtained by other synthetic methods. 
Garcia Lda et al. [4] obtained biocompatibility results 
that fully correspond to the results of this study in the 
absence of inflammation and a significant increase in the 
thickness of fibrous capsule after 30 days of subcutaneous 
implantation of calcium aluminate cement (EndoBinder), 
calcium silicate cement (mineral trioxide aggregates) and 
calcium hydroxide in rats. Despite the fact that EndoBinder 
releases a lower amount of calcium ions, it caused a tissue 
reaction similar to that induced by MTA and calcium hy-
droxide in all observation periods. The authors explain this 
by the methodology applied in this in vivo study. Garcia 
Lda et al. [4] concluded that, from the biological point of 
view, EndoBinder became a promising option in endodon-
tic therapy, but with the recommendation that additional 
research into the biological and physical-chemical proper-
ties of this new cement could be carried out before its ap-
plication in the endodontic therapy of human populations.
Aminozarbian et al. [27] confirmed that the inflamma-
tory response of the tissue to the implantation of CAAC 
calcium aluminate cement and the mixture of volostonite 
and calcium aluminate cement of WOLCA was, after 30 
days, in rats comparable to MTA, which is in accordance 
with our findings, while CAAC Plus did not confirm bio-
compatibility as it induced a more intense inflammatory 
response than MTA. The authors explain this by the com-
position of CAAC Plus cement, with adding 5% Na-HMP 
dispersant in order to improve its properties, which on 
the other hand negatively affected biocompatibility [27].
Aguilar et al. [11] confirmed a better tissue reaction 
after calcium aluminate cement EndoBinder was compared 
to GMTA after 42 days of subcutaneous implantation of 
these materials in rat tissue. This is explained by the pro-
cess of EndoBinder’s synthesis, low Ca content, which re-
sults in the release of a smaller amount of calcium ions, 
making it less irritant and cytotoxic to the tissues, without 
compromising its antimicrobial properties [11].
The reaction of the tissue to the empty tubes (nega-
tive control) in this experiment is similar to the findings 
of other researchers [19, 28]. After seventh day, the most 
pronounced inflammatory response was confirmed, and 
this initial inflammatory reaction to the empty tubules was 
explained by the reaction to the surgical implantation pro-
cedure [19, 28].
Results of the biocompatibility of ALBO-CSHA ob-
tained in this study correspond to the findings of Petrović 
et al. [17] and Saghiri et al. [29]. In their studies, at the end 
of the observation, there was no significant difference in 
the tissue inflammatory response to CS-HA and MTA, i.e. 
BioAggregate, nanostructured tricalcium silicate cement 
with the addition of calcium phosphate, and MTA after 
subcutaneous implantation in rats. The authors explain this 
finding by the fact that calcium-containing good biological 
properties owe a common ability to released calcium ions, 
and a similar reaction is expected in a situation where the 
new calcium silicate system comes into contact with tissue 
fluids. In the study by Petrović et al. [17], the application of 
a special synthesis method further favored the bioactivity 
of the examined CS-HA. 
Contrary to this, Batur et al. [30] have come up with 
results that are inconsistent with the results of this study, 
as they confirmed statistically significantly better tissue 
response and a weaker inflammatory response of DiaRoot 
BioAggregate compared to MTA. A possible reason for a 
better BioAggregate result may be the fact that their re-
search was done in vivo conditions on laboratory animals 
(Sprague–Dawley rats), as opposed to previous in vitro 
studies, in which no statistically significant difference was 
found between MTA and BioAggregat [30].
CONCLUSION
The subcutaneous tissue of rats showed good tolerance of 
calcium aluminate nanostructured biomaterials and com-
parable to nanostructured calcium silicate ALBO-CSHA 
and commercial calcium silicate cement (MTA). The bio-
compatibility of this nanomaterial should be verified in 
other experimental studies before clinical screening on 
human population.
NOTE
This paper is part of a research thesis entitled „Biocom-
patibility nanostructured biomaterials based on calcium 
aluminate“ by Ognjenka Janković.
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САЖЕТАК
Увод/Циљ Циљ овог рада је био да се провери биокомпа-
тибилност новосинтетисаног наноструктурног материјала 
на бази калцијум-алумината после имплантације у поткожно 
ткиво пацова. 
Методе У истраживање је укључено 18 пацова старости 
10–11 седмица, који су подељени у две експерименталне 
групе (n = 9). Код свих животиња је урађена инцизија на 
леђима и формирана су два џепа дубине 15 mm у којa су 
аплициране стерилне полиетиленске тубице са тестним 
материјалима (ALBO-CA, ALBO-CSHA и контрола МТА). По 
шест пацова сваке групе је жртвовано у три опсервациона 
периода (7, 15 и 30 дана). Патохистолошки су анализирани 
инфламација, крварење, фиброзна капсула и интегритет 
ткива око имплантираног материјала.
Резултати После седам дана ALBO-CA и ALBO-CSHA су пока-
зали бољи ткивни одговор у односу на МТА са статистички 
значајном разликом у интензитету инфламације (p = 0,2781). 
Разлика у васкуларној конгестији и дебљини фиброзне кап-
суле после имплантације материјала ALBO-CA у односу на 
МТА је такође била статистички значајна (p = 0,5567). На крају 
евалуационог периода од 30 дана забележен је идентичан 
инфламаторни одговор растреситог везивног ткива на 
месту имплантације ALBO-CA, ALBO-CSHA и МТА (оцена 0,7). 
Констатовано је формирање дебеле или умерено дебеле 
фиброзне капсуле, која је била најдебља код ALBO-CA (оцена 
3,7). Статистички значајне разлике између анализираних 
параметара после 30 дана није било.
Закључак Новосинтетисани ALBO-CA је показао задовоља-
вајућу ткивну реакцију и потврдио биокомпатибилност по-
сле имплантације у поткожно ткиво пацова.
Кључне речи: наноматеријали; калцијум-алуминати; кал-
цијум-силикати, ткивна реакција
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